European Personalised Medicine and Pharmacogenomics Markets

Published by: Frost & Sullivan

Published: Oct. 16, 2006 - 73 Pages

Table of Contents

1. Executive Summary

1. Executive Summary

1. Executive Summary

2. Glossary Terms and Exchange Rates

1. Glossary of Terms and Exchange Rates

1. Glossary of Terms

2. Exchange Rates

3. Industry Challenges

1. Identification of the Challenges Facing the European Personalised Medicine and Pharmacogenomics Market

1. Identification of the Challenges Facing the European Personalised Medicine and Pharmacogenomics Market

4. Market Engineering Research for the European Personalised Medicine and Pharmacogenomics Market

1. Forecast for the European Personalised Medicine and Pharmacogenomics Market

1. European Personalised Medicine and Pharmacogenomics Market

2. Research and Methodology

3. Market Segmentation

4. Market Engineering Measurements

5. Market Drivers

a. Early Detection is the Primary Factor Affecting Survival Rates

b. Increasing Awareness Ensures Revenue Growth

c. Emphasis on Preventive Medicine Promotes Pharmacogenomics

d. Diagnostic Companies Gain Significant Momentum through Pharmacogenomics

e. Aging Population Contributes to Increase Pharmacogenomic Testing

f. Pharmacogenomic Testing Provides Answers when Making Life/Health Related Decisions

6. Regulations

7. Revenue Forecast

8. Geographic Trends

9. Trends by Geographic Region-Part 1

10. Trends by Geographic Region -Part 2

11. Technology Trends

12. End User Trends

13. Market Share Analysis

5. Market Engineering Strategic Recommendations

1. Strategic Recommendations

1. Strategic Recommendations

6. Database of Key Industry Participants

1. Database of Key Industry Participants

1. Key Industry Participants

7. Decision Support Databases

1. Decision Support Databases

1. Decision Support Databases

List of Figures

Chapter 2

Personalised Medicine and Pharmacogenomics Market: Exchange Rates (Europe), 2006

Chapter 3

Personalised Medicine and Pharmacogenomics Market: Impact of Top Industry Challenges (Europe), 2006-2012

Chapter 4

Personalised Medicine and Pharmacogenomics Market: Market Drivers Ranked in Order of Impact (Europe), 2006-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Europe), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Per Cent of Revenues by Geographic Region (Europe), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Germany), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (France), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (UK), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Italy), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Spain), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Benelux), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Revenue Forecasts (Scandinavia), 2002-2012

Personalised Medicine and Pharmacogenomics Market: Competitive Structure (Europe), 2005

Personalised Medicine and Pharmacogenomics Market: Market Share Trends of Major Participants (Europe), 2005

Chapter 7

Decision Support Database: Breast Cancer Incidence in'000 (Europe), 2002-2012

Decision Support Database: Breast Cancer Mortality (Europe), 2002-2012

Decision Support Database: Population 65 Plus in Million (Europe), 2002-2012

Decision Support Database: Colon Rectum Cancer Mortality (Europe), 2002-2012

Decision Support Database: Total Healthcare Expenditure in Billion USD (Europe), 1999-2006

Abstract

Research Overview

The Frost & Sullivan research service titled European Personalised Medicine and Pharmacogenomics Market provides an overview of the pharmacogenomic tests, together with the revenues, key market drivers, restraints, and trends in the market. This apart, it provides strategic solutions to the vendors to gain advantage in this growing market, and also discusses the available pharmacogenomics options in detail for other areas to determine a clinical course of therapeutic treatments; for example, cardio-vascular disease, stroke and type II diabetes.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

• Clinical Diagnostics
• Drug Discovery

Technologies

The following technologies are covered in this research:

• Pharmacodiagnostic: It is a genetic test to detect the presence or absence of, or change in, a particular gene or chromosome. This can be done directly, by analysing the chromosomes or DNA of an individual, or indirectly, by examining the products of their DNA, such as RNA or proteins. In the context of pharmacogenetics, the same types of direct or indirect tests for a gene sequence or gene product are applied to test for response to a medicine.
• Pharmacogenetics: It is the study of how genetic variation between individuals affects their response to medicines. The term pharmacogenetics reflects the merging of pharmacology, which is the study of how medicines work in the body, and genetics, which is the study of how characteristics are inherited.
• Pharmacogenomics: This term is not distinctly differentiated from pharmacogenetics, but implies the examination of whole genomes or substantial numbers of genes in order, for example, to identify putative targets for medicines or to identify large-scale differences in the patterns of gene expression in response to chemical compounds.

Market Overview

Potential for Early Disease Detection Promoting Market Growth

The ability to detect a disease in its very early stage and the subsequent advantages of better clinical outcomes are proving major drivers for the growing adoption of pharmacogenomic tests across Europe. Pharmacogenomics can be used to detect a predisposition toward a particular disease and for growing disease markets such as cardiovascular diseases, diabetes and cancer, a genetics-based test could identify patients for long-term prophylactic therapy. This, in turn will decrease the use of expensive therapies and invasive procedures, in addition to reducing bed occupancy and lessening the burden on the healthcare system. Considering these advantages, governments across Europe have initiated campaigns to encourage the population to be screened on certain types of diseases such as cancer, which have significantly helped better patient management.

Despite all this, inherent problems regarding the time and cost associated with the development of diagnostic tests remain major restraints for market growth. Moreover, obtaining intellectual property for pharmacogenomic tests pose significant challenges for companies. "As companies identify novel compounds, a strong intellectual property system is necessary to stimulate investment in innovation," notes the analyst of this research service." It is essential that the European Governments' patent systems offer protection for innovations relating to personalised medicine, as well as high quality patent examination that allows patents of appropriate scope and quality."

Hybridisation Techniques Remain Dominant

With regard to technology, hybridisation techniques tend to be the major technologies utilised in the field of pharmacogenomics, and fluorescence in-situ hybridisation (FISH) continues to be widely used due to its ability to detect a variety of chromosomal and genetic aberrations such as molecular translocation deletions specific to each entity of haematological malignancies in a single non-dividing interphase cell. The HER-2/neu gene is a prime example of a successful pharmacogenomic test that has both diagnostic and prognostic value. Abbott Diagnostics' (Vysis) PathVysion is a FISH-based test that has an addition of Genetech's Herceptin for patients who may require treatment. The technology is capable of diagnosing multiple gene copies characteristic of HER-2/neu over expression in breast cancer. Developments in the microarray and genotype assay technologies are also expected to aid the growth of the pharmacogenomics during the next few years.

"Among the regional markets, the German pharmacogenomics market was the largest revenue generator in 2005, primarily due to the high level of awareness about pharmacogenomics among medical professionals as well as the public," says the analyst. "Following the German market was France, which has radically changed the emphasis on disease management uniformity, focussing more on individual patient management, as the technology of personalised medicine has become inexpensive and more readily available."

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.